Tender Offer | ₹1,100.00 Crores | Listed at BSE, NSE | Thu, Jun 4, 2026 - Wed, Jun 10, 2026
Zydus Lifesciences Ltd Buyback is a tender offer for the repurchase of up to 0.87 crore equity shares, representing 0.87% of the total paid-up equity share capital at a buyback price of ₹1260 per share with a face value of ₹1 per share, aggregating to ₹1,100.00 crores.
The record date for determining eligible shareholders is May 29, 2026. Shareholders holding equity shares as on the record date are eligible to participate in the buyback.
The buyback opens on Jun 4, 2026 and closes on Jun 10, 2026, with the last date for receipt of tender forms being Jun 10, 2026.
The finalisation of buyback acceptance is expected on Jun 16, 2026, followed by settlement of bids on Jun 17, 2026.
ICICI Securities Ltd. is the Manager to the Buyback, MUFG Intime India Pvt.Ltd. is the Registrar and ICICI Securities Ltd. is the Registered Broker to the Buyback.
Investors are advised to refer to the Zydus Lifesciences Ltd Letter of Offer for detailed information, including eligibility criteria, entitlement ratio, acceptance methodology, and tax implications.
Offer Opening Date
Thu, Jun 4, 2026
Offer Closing Date
Wed, Jun 10, 2026
Buyback Price
₹1260 per share
Record Date
May 29, 2026
| Category | Entitlement Ratio | Shares Offered |
|---|---|---|
| Small Shareholders | 5 : 49 | 13,09,524 |
| General Category | 7 : 937 | 74,20,634 |
Note:
Small Shareholders are retail shareholders under SEBI regulations.
General Category includes all other eligible shareholders.
Entitlement ratio is based on fully paid-up equity shares held on the record date.
Zydus Lifesciences Ltd's revenue decreased by 17% and profit after tax (PAT) dropped by 38% between the financial year ending with March 31, 2026 and March 31, 2025.
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total Income | 13,151.50 | 15,812.50 | 11,903.50 |
| Profit After Tax | 3,559.80 | 5,774.90 | 3,441.50 |
| NET Worth | 23,671.70 | 21,190.10 | 15,716.50 |
| Reserves and Surplus | 23,571.10 | 21,089.50 | 15,615.90 |
| Total Borrowing | 7,431.10 | 8,338.70 | 6,173.50 |
| Amount in ₹ Crore | |||
Zydus Lifesciences Limited is an Indian Pharmaceutical company that offers healthcare services globally.
The company manufactures formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical, etc.), animal health products, and wellness products.
Zydus Lifesciences Limited has over 30 manufacturing plants worldwide, including India, Germany, Brazil & USA. Zydus Lifesciences Limited is the fourth-largest pharmaceutical company in India. Zydus Lifesciences was formerly known as Cadila Healthcare Limited.
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Apr-2026 | 963.00 | 835.85 | 911.60 |
| Mar-2026 | 936.00 | 835.85 | 898.28 |
| Feb-2026 | 947.70 | 863.50 | 905.49 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Apr-2026 | 962.90 | 835.50 | 912.02 |
| Mar-2026 | 936.15 | 858.00 | 898.40 |
| Feb-2026 | 947.55 | 863.65 | 905.51 |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Zydus Lifesciences Ltd
Zydus Corporate Park, Scheme No. 63,
Khoraj (Gandhinagar), 536, Sarkhej-Gandhinagar Hwy
Near Vaishnodevi Circle, Ahmedabad, 382481
Ahmedabad, Gujarat, 382481
Lead Manager(s)
Registered Broker
The Zydus Lifesciences Buyback 2026 opens on June 4, 2026, and closes on June 10, 2026.
Last date to be eligible to participate in buyback is May 27, 2026.
The Zydus Lifesciences Buyback 2026 is a Tender Offer.
Zydus Lifesciences Buyback 2026 Schedule
| Buyback Opening Date | June 4, 2026 |
| Buyback Closing Date | June 10, 2026 |
| Last Date for receipt of Tender Forms | June 10, 2026 |
| Finalisation of Buyback Acceptance | June 16, 2026 |
| Last Date for settlment of bids | June 17, 2026 |
| Last Date for Extinguishment of Shares | June 29, 2026 |
The Zydus Lifesciences Buyback 2026 is being offered at Rs ₹1260 per share.
| Category | Entitlement Ratio | Shares Offered |
|---|---|---|
| Small Shareholders | 5 : 49 | 13,09,524 |
| General Category | 7 : 937 | 74,20,634 |
Note:
Small Shareholders are retail shareholders under SEBI regulations.
General Category includes all other eligible shareholders.
Entitlement ratio is based on fully paid-up equity shares held on the record date.
The issue size of Zydus Lifesciences Buyback 2026 is 87,30,158 equity shares at ₹1260 per share aggregating up to ₹1,100.00 Crores.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Zydus Lifesciences Buyback 2026 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
